May 12, 2022

Real-life family stories, social channels and website provide
myopia management resources for U.S. parents


SAN RAMON, CALIF., May 12, 2022—CooperVision today announced the launch of a digital ecosystem designed to amplify real-life myopia stories from age-appropriate* children and to more thoroughly educate parents of affected children about the condition. Developed specifically for the U.S. market, the online resources also support eye care professionals (ECPs) in helping families learn about myopia control and contact lens hygiene beyond the exam room.

With at its core, the initiative extends across YouTube, Facebook, and Instagram, the three most-used social media platforms in the U.S.1 Together, families can watch the stories of eight-year-old gymnast twins Madeline and Olivia, 11-year-old hockey player Adam and 11-year-old aspiring Olympic ice skater Violet. MiSight® 1 day contact lenses provide the vision correction2,3±‡ and lifestyle convenience needed in their active lives4, while slowing the progression of myopia2 to benefit their long-term eye health.

Other feature stories and videos take families through myopia management milestones such as learning to insert and remove contact lenses, and managing screen time and near work. A companion online forum hosted on parenting website TinyBeans connects parents with eye care experts, who will directly respond to questions about their child’s vision. The vibrant, family-friendly resources extend eye health conversations from the eye care practice into the living room, bolstering understanding and commitment in managing a child’s myopia.

This new digital ecosystem advances the myopia education and awareness-building objectives that started with CooperVision’s parent education campaign “Take Control: Myopia & You.” Since that debuted last fall, its efforts have amassed 330 million impressions and nearly 40 million engagements through consumer media coverage, social media, and other online platforms. One in five parents exposed to the campaign reported reaching out to their ECP to learn more.

“The MiSight® digital ecosystem has been helpful to share with parents so that they can learn more about myopia control for age-appropriate children and MiSight® 1 day at their own pace,” said Andrew Neukirch, OD, Carillon Vision Care, who participated in the program’s pilot phase. “Hearing directly from other parents and children has been great for building trust in the treatment and for sharing tips on contact lens wear. CooperVision’s commitment and leadership has been vital to the growth of myopia management and control in my practice and across the country.”


*Indications for use: MiSight® 1 day (omafilcon A) soft (hydrophilic) contact lenses for daily wear are indicated for the correction of myopic ametropia and for slowing the progression of myopia in children with non-diseased eyes, who at the initiation of treatment are 8-12 years of age and have a refraction of -0.75 to -4.00 diopters (spherical equivalent) with ≤ 0.75 diopters of astigmatism. The lens is to be discarded after each removal.

†Compared to a single vision 1 day lens over a 3 year period.

± VA (LogMAR) > 6/6 (20/20) at all visits from dispensing to 6-year visit.

‡ Children aged 8-12 at the initiation of treatment.

҂ 77% strongly agree, 20% somewhat agree.

# # #


About CooperVision
CooperVision, a division of CooperCompanies (NYSE:COO), is one of the world’s leading manufacturers of contact lenses. The company produces a full array of daily disposable, two-week and monthly soft contact lenses that feature advanced materials and optics, and premium rigid gas permeable lenses for orthokeratology and scleral designs. CooperVision has a strong heritage of addressing the toughest vision challenges such as astigmatism, presbyopia, childhood myopia, and highly irregular corneas; and offers the most complete portfolio of spherical, toric and multifocal products available. Through a combination of innovative products and focused practitioner support, the company brings a refreshing perspective to the marketplace, creating real advantages for customers and wearers. For more information, visit

About CooperCompanies
CooperCompanies ("Cooper") is a global medical device company publicly traded on the NYSE (NYSE:COO). Cooper operates through two business units, CooperVision and CooperSurgical. CooperVision brings a refreshing perspective on vision care with a commitment to developing a wide range of high-quality products for contact lens wearers and providing focused practitioner support. CooperSurgical is committed to advancing the health of women, babies and families with its diversified portfolio of products and services focusing on medical devices and fertility & genomics. Headquartered in San Ramon, Calif., Cooper has a workforce of more than 12,000 with products sold in over 100 countries. For more information, please visit

Media Contact
Ryan Young, Communications Coordinator, McDougall Communications or +1-585-434-2151


1 Auxier, B., & Anderson, M. (2022, January 31). Social media use in 2021. Pew Research Center: Internet, Science & Tech. Retrieved April 7, 2022, from

2 Chamberlain P, et al. A 3-year Randomized Clinical Trial of MiSight® Lenses for Myopia Control. Optom Vis Sci. 2019; 96(8)556-567.

3 Chamberlain P, Arumugam B, Jones D et al. Myopia Progression in Children wearing Dual-Focus Contact Lenses: 6-year findings. Optom Vis Sci 2020;97(E-abstract):200038.

4 Walline JJ, et al. Benefits of contact lens wear for children and teens. Eye Contact Lens. 2007;33(6 Pt 1):317-21.

5 CVI data on file 2022. U.S. CooperVision online survey: Vision Source ECP MiSight Perspectives; n=101 ECPs that prescribe MiSight® 1 day.